<DOC>
	<DOCNO>NCT00602537</DOCNO>
	<brief_summary>This study compare safety effectiveness antidepressant therapy versus mood stabilize therapy treat people bipolar type II major depression .</brief_summary>
	<brief_title>Antidepressant Therapy Treating Bipolar Type II Major Depression</brief_title>
	<detailed_description>Bipolar type II ( BP II ) depression affect 2.5 % U.S. adult population . People BP II disorder experience manic episode characteristic BP I disorder , rather experience modest mood swing great number major depressive episode ( MDEs ) . These MDEs associate high rate disease death . The treatment BP II depression remain challenge clinician . Mood stabilizer ( MS ) monotherapy current recommend treatment BD II MDE , reason believe antidepressant drug ( AD ) monotherapy could also effective treatment . However , concern AD-induced manic switch episode limited use treatment option . Preliminary study use ADs fluoxetine venlafaxine show success treat lower manic switch rate BP II MDE . This study compare safety effectiveness AD monotherapy versus MS monotherapy treat people BP II major depression . Participation double-blind study last 9 month . After screen , include medical psychiatric history review , physical exam , electrocardiogram ( EKG ) test , clinical laboratory test , urine-based drug test , pregnancy test applicable , participant randomly place one two treatment group . Participants AD monotherapy group treat venlafaxine , participant MS monotherapy group treat lithium . During first 12 week , total nine study visit last 45 60 minute . In visit , participant receive study drug undergo various assessment , include review medication history side effect , vital sign measurement , questionnaire depression daily function . Blood sample take visit . Participants respond well initial 12 week therapy either drug option continue treatment 6 additional month . During time , participant continue assign treatment attend five monthly study visit repeat previous assessment procedure . For information relate study , please follow link : http : //clinicaltrials.gov/show/NCT00044616</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Meets DSMIV criterion Axis I bipolar II disorder Meets DSMIV criterion Axis I major depressive episode Score 16 17item HAMD rating scale Not take monoamine oxidase inhibitor ( MAOI ) 2 week prior study entry Willing use effective form birth control throughout study History mania Current primary Axis I diagnosis bipolar II disorder Alcohol drug dependence within 3 month prior study entry Contraindication treatment venlafaxine lithium Unstable medical condition ( e.g. , thyroid disease , hypertension , angina pectoris ) Pregnant breastfeed Experiencing suicidal thought Requires hospitalization Requires concurrent neuroleptic MS therapy Requires concurrent AD therapy Current psychotic feature Inadequate trial therapy time initial screen visit History intolerance either venlafaxine lithium Unlikely participate 36week trial Presence apparent secondary gain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Bipolar Type II Disorder</keyword>
	<keyword>Hypomania</keyword>
	<keyword>Antidepressant</keyword>
	<keyword>Mood Stabilizer</keyword>
	<keyword>Venlafaxine</keyword>
	<keyword>Lithium Carbonate</keyword>
	<keyword>Major Depressive Episode</keyword>
	<keyword>Hypomanic Episodes</keyword>
	<keyword>Prevention Depression Relapse</keyword>
</DOC>